Clinical Trial

Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a post-approval commitment study to evaluate efficacy, and safety of two dosing regimens of secukinumab (AIN457), 300 mg every four weeks (Q4W) and every two weeks (Q2W), in Chinese adult patients with moderate to severe hidradenitis suppurativa (HS).
Protocol Amendment History 2 changes
notable Trial sites expanded: 1 -> 7 locations 2026-07-11
critical Recruitment opened 2026-06-04
Trial Details
NCT Number NCT07489573
Lead Sponsor Novartis Pharmaceuticals
Conditions Hidradenitis Suppurativa (HS)
Enrollment 36 participants
Start Date 2026-06-01
Primary Completion 2029-09-25 (estimated)
Study Completion 2029-11-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-10